Table 1.
PD-1 and PD-L1 expression changes on malignant B-cells and tumor microenvironment TL surfaces, in CLL ( Table 1A ) or RS ( Table 1B ) context.
| A (CLL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ref. | Number of patients | PD-1 expression | PD-L1 expression | ||||||
| Lymph node | Bone Marrow/Peripheral Blood | Lymph Node | Bone Marrow/Peripheral Blood | ||||||
| B-CLL | TIL | B-CLL | TIL | B-CLL | TIL | B-CLL | TIL | ||
| (95) | 13 | Yes | Yes | Yes (PB) | UD | No | UD | UD | UD |
| (96) | 117 | Yes | Yes | Yes (PB) | Yes (PB) | Yes | UD | Yes (PB) | UD |
| (94) | 68 | Yes | Yes | UD | UD | Yes | UD | Yes (PB) | UD |
| (99) | 16 | Yes | UD | UD | UD | UD | UD | UD | UD |
| (100) | 39 | Yes | Yes | UD | UD | No | UD | UD | UD |
| (91) | 58 | No | Yes | UD | UD | UD | UD | UD | UD |
| (98) | 58 | Yes | Yes | Yes | UD | Yes | UD | No | UD |
| (92) | 37 | UD | UD | UD | UD | No | UD | UD | UD |
| (97) | 112 | UD | UD | UD | UD | UD | UD | Only on MNC | UD |
| (101) | 39 | UD | UD | UD | Yes | UD | UD | UD | UD |
| (102) | 16 (4 with tumor-invaded tissues) | Yes | Yes | UD | UD | Yes | Yes | UD | UD |
| (103) | 18 | UD | UD | UD | UD | No | UD | No | UD |
| B (Richter Syndrome) | |||||||||
| Ref. | Number of patients | PD-1 expression | PD-L1 expression | ||||||
| Lymph node | Bone Marrow/Peripheral Blood | Lymph Node | Bone Marrow/Peripheral Blood | ||||||
| Richter cells | TIL | Richter cells | TIL | Richter cells | TIL | Richter cells | TIL | ||
| (100) | 15 | Yes | Yes | UD | UD | Yes | No | UD | UD |
| (99) | 17 | Yes | UD | UD | UD | Yes | UD | UD | UD |
| (102) | 9 (6 with tumor-invaded tissues) | Yes | Yes | UD | UD | Yes | No | UD | UD |
| (103) | 15 (5 with tumor-invaded tissues) | UD | UD | UD | UD | Yes | No | UD | UD |
PD-1, programmed death 1; PD-L1, programmed death ligand 1; B-CLL, CLL malignant B-cells; BM, bone marrow; LN, lymph node; MNC, mononuclear cells; PB, peripheral blood; RS-MO, RS microenvironment; TIL, tumor-infiltrating lymphocytes; UD, undetermined.